ArticleMetabolomics : Official journal of the Metabolomic Society2026
Comparative urinary metabolomics reveals unique and shared pathways in COVID-19 and liver diseases.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionThe COVID-19 pandemic and liver diseases both cause significant metabolic disturbances, yet the specific mechanisms driving these changes remain poorly understood.
objectivesThis study aimed to elucidate and compare the urinary metabolomic profiles of COVID-19 patients, individuals with liver diseases, and healthy controls to determine common and unique metabolic signatures between diseases.
methodsUntargeted metabolomic profiling was performed using liquid chromatography-mass spectrometry (LC-MS) on urine samples from COVID-19 patients (n = 102), liver disease patients (n = 100), and healthy controls (n = 101). Differential metabolite abundance, pathway enrichment, network topology, and Random Forest-based machine learning analyses were performed.
resultsBoth COVID-19 and liver disease exhibited extensive metabolic reprogramming. COVID-19 patients showed suppression of Vitamin B6 and purine metabolism, indicating impaired energy production and antioxidant defense. Liver disease patients exhibited reduced primary bile acid biosynthesis and pantothenate metabolism, reflecting hepatic dysfunction. Random Forest models robustly discriminated disease from healthy states, with binary models for COVID-19 and liver disease achieving AUCs of 0.998, and a multiclass model distinguishing all three groups with 91.9% accuracy. Both conditions shared perturbations in amino acid and steroid-related pathways, reflecting common systemic stress. Importantly, unique metabolites, such as N-Acetylvaline, Succinyladenosine, and S-adenosylhomocysteine in COVID-19, and 3-Hydroxysebacic acid, Asn-Trp, and bile acid derivatives in liver disease, emerged as highly specific biomarkers, highlighting systemic viral stress versus chronic hepatic metabolic adaptation and warranting future validation.
conclusionThese findings enhance our understanding of disease-specific metabolic remodelling and point to potential biomarkers for diagnosis and therapeutic targeting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.